Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?

Related Articles

Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?

Molecules. 2019 Jul 24;24(15):

Authors: Tatham LM, Liptrott NJ, Rannard SP, Owen A

In recent years, advances in pharmaceutical processing technologies have resulted in development of medicines that provide therapeutic pharmacokinetic exposure for a period ranging from weeks to months following a single parenteral administration. Benefits for adherence, dose and patient satisfaction have been witnessed across a range of indications from contraception to schizophrenia, with a range of long-acting medicines also in development for infectious diseases such as HIV. Existing drugs that have successfully been formulated as long-acting injectable formulations have long pharmacokinetic half-lives, low target plasma exposures, and low aqueous solubility. Of the statins that are clinically used currently, atorvastatin, rosuvastatin, and pitavastatin may have compatibility with this approach. The case for development of long-acting injectable statins is set out within this manuscript for this important class of life-saving drugs. An overview of some of the potential development and implementation challenges is also presented.

PMID: 31344834 [PubMed - in process]